A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label, Phase 1b dose escalation and expansion study to determine the maximum
tolerated dose (MTD) of OP-1250 in combination with palbociclib (Ibrance®️, Pfizer Inc.).
Purpose of study is to evaluate the safety and pharmacokinetic (PK) profile, and estimate the
preliminary anti-tumor activity of the combination in adult subjects with hormone
receptor-positive (ER+ / HER2-) advanced or metastatic breast cancer (MBC).